Statistical Analyst - ADaM Programming (Hybrid)
AbbVie
Summary
The Statistical Analyst is an integral role in the research and development of new pharmaceutical products. The primary responsibilities for this role include the analysis and reporting of clinical trial data without supervision for routine activities and with supervision for more complex activities. The Statistical Analyst interfaces with Statistics, Clinical Data Strategy & Operations and Development Operations.
Job description
Responsibilities
- Leads the statistical programming activities for routine studies.
- Create documentation for regulatory filings including reviewers guides and data definition documents
- Participate in the development of standard SAS Macros, as well as, presenting information on existing Macros
- Produce dynamic and static data visualizations to communicate quantitative analyses.
- Develop SAS programs for the creation of ADaM data sets following CDISC standards.
- Develop SAS programs for the creation of Tables, Listings and Figures.
- Validation of ADaM data sets. Validation of Tables, Listings and Figures.
- Create specifications for the structure of ADaM data sets for individual studies and integrated data
Requirements
- MS in Statistics, Computer Science or a related field with 2+ years of relevant experience OR BS in Statistics, Computer Science or a related field with 4+ years of relevant experience
- Experience in pharmaceutical clinical trials
- Demonstrated practical understanding of SAS programming related to drug development
- Experience creating and reviewing ADaM datasets for analysis
- Ability to communicate clearly both oral and written
- Basic understanding of CDISC Standards
- Basic understanding of the drug development process
Benefits
- Paid time off
- Medical, Dental & Vision
- 401(k)
- Short-term incentive programs
Company overview
AbbVie is a global biopharmaceutical company that discovers, develops, and markets advanced therapies for some of the world's most complex and serious diseases. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie has established itself as a leader in immunology, oncology, neuroscience, eye care, and virology. The company's flagship product, Humira (adalimumab), was one of the world's top-selling drugs for treating autoimmune conditions like rheumatoid arthritis and Crohn's disease. AbbVie maintains a robust pipeline of innovative medicines and has expanded its portfolio through strategic acquisitions, including Allergan in 2020. With research facilities across the United States and globally, AbbVie focuses on advancing science to improve patient outcomes while maintaining strong commercial operations worldwide. The company operates with a patient-centric approach and invests significantly in research and development to address unmet medical needs across multiple therapeutic areas.